BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30
• 31

• Press Releases

  Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop

  May 23, 2025

   · 

  1 min read
• Press Releases

  SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2024 Annual Report

  May 23, 2025

   · 

  4 min read
• Press Releases

  OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025

  May 23, 2025

   · 

  6 min read
• Press Releases

  Faron Announces New Data that Highlight Patient Populations with Cancer that are Most Likely to Benefit from First-in-class Immunotherapy Bexmarilimab

  May 23, 2025

   · 

  7 min read
• Press Releases

  Secarna Pharmaceuticals to Present New Data and Clinical Strategy for Lead Antisense Oligonucleotide Program SECN-15 at ASCO 2025

  May 23, 2025

   · 

  3 min read
• Press Releases

  Sol-Gel Reports First Quarter 2025 Results

  May 23, 2025

   · 

  7 min read
• Press Releases

  UniXell Biotechnology announces the first patient dosed with UX-DA001, an investigational autologous iPSC based cell therapy for the treatment of Parkinson’s disease, in its Phase 1 study

  May 23, 2025

   · 

  4 min read
• Press Releases

  Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025

  May 23, 2025

   · 

  1 min read
• Press Releases

  Perimeter Partners with Intermountain Health to Study the Potential Clinical, Social and Economic Benefits of Using OCT and AI to Reduce Cancer Reoperations

  May 23, 2025

   · 

  6 min read
• Press Releases

  ENHERTU® (trastuzumab deruxtecan) Receives Time-Limited Reimbursement Recommendation from Canada’s Drug Agency for Gastric Cancer

  May 23, 2025

   · 

  6 min read